Skip to main content

Table 1 Demographic and clinical characteristics of the participants aged ≥75 years in the cohortstudy

From: Assessing the effectiveness of statin therapy for alleviating cerebral small vessel disease progression in people ≥75 years of age

  All (n = 827) Non-statin group (n = 698) Statin group (n = 129) P valuea
Clinical parameters
 Female (n [%]) 465 (56.2) 392 (56.2) 73 (56.6) 0.928
 Age (years) 78.08 ± 2.38 78.00 ± 2.38 78.50 ± 2.39 0.028
 Current smoking (n [%]) 257 (31.1) 218 (31.2) 39 (30.2) 0.822
 Alcohol consumption (n [%]) 271 (32.8) 232 (33.2) 39 (30.2) 0.504
 Hypertension (n [%]) 554 (67.0) 472 (67.6) 82 (63.6) 0.368
 Antihypertensive medication (n [%]) 425 (51.4) 367 (52.6) 58 (45.0) 0.112
 Diabetes (n [%]) 98 (11.9) 79 (11.3) 19 (14.7) 0.271
 Lowering glucose medication (n [%]) 91 (11.0) 73 (10.5) 18 (14.0) 0.244
 Dyslipidemia (n [%]) 586 (70.9) 490 (70.2) 96 (74.4) 0.333
 Ischemic heart disease (n [%]) 506 (61.2) 422 (60.5) 84 (65.1) 0.319
 Peripheral artery disease (n [%]) 114 (13.8) 93 (13.3) 21 (16.3) 0.371
 Need statins for primary prevention (n [%]) 720 (87.1) 591 (84.7) 129 (100.0)
 Statins (n [%]) 129 (15.6) 0 (0.0) 129 (100.0)
 Simvastatin 46 (5.6) 0 (0.0) 46 (35.7)
 Atorvastatin 16 (1.9) 0 (0.0) 16 (12.4)
 Lovastatin 7 (0.8) 0 (0.0) 7 (5.4)
 Fluvastatin 11 (1.3) 0 (0.0) 11 (8.5)
 Pravastatin 13 (1.6) 0 (0.0) 13 (10.1)
 Rosuvastatin 36 (4.4) 0 (0.0) 36 (27.9)
 Antiplatelet medication (n [%]) 187 (22.6) 155 (22.2) 32 (24.8) 0.517
 Body mass index (kg/m2) 24.38 ± 2.53 24.36 ± 2.55 24.52 ± 2.39 0.506
 Heart rate (bpm) 70.67 ± 8.64 70.71 ± 8.73 70.48 ± 8.12 0.783
 SBP (mm Hg) 147.92 ± 16.69 148.20 ± 16.52 146.36 ± 17.58 0.250
 DBP (mm Hg) 75.82 ± 8.29 75.93 ± 8.24 75.21 ± 8.59 0.366
Biochemical parameters
 TCHO (mmol/L) 4.68 ± 0.75 4.72 ± 0.76 4.49 ± 0.68 0.001
 TG (mmol/L) 1.53 ± 0.49 1.56 ± 0.51 1.37 ± 0.30 < 0.001
 HDL-C (mmol/L) 1.16 ± 0.35 1.15 ± 0.35 1.25 ± 0.35 0.002
 LDL-C (mmol/L) 2.82 ± 0.68 2.86 ± 0.68 2.62 ± 0.63 < 0.001
 FPG (mmol/L) 5.42 ± 1.31 5.44 ± 1.32 5.30 ± 1.22 0.260
Brain magnetic resonance imaging
 WMH (mL) 5.02 (3.53, 6.37) 5.18 (3.73, 6.51) 4.25 (2.82, 5.48) < 0.001
 WMH-to-ICV ratio (%) 0.38 (0.27, 0.48) 0.40 (0.29, 0.49) 0.32 (0.22, 0.40) < 0.001
 Prevalence of Fazekas scale ≥2 (n [%]) 114 (13.8) 104 (14.9) 10 (7.8) 0.031
 Prevalence of lacunes (n [%]) 98 (11.9) 90 (12.9) 8 (6.2) 0.031
 Prevalence of Virchow-Robin spaces (n [%]) 140 (16.9) 126 (18.1) 14 (10.9) 0.045
 Prevalence of microbleeds (n [%]) 67 (8.1) 56 (8.0) 11 (8.5) 0.847
  1. Data are expressed as mean ± standard deviation, median with interquartile range, or numbers with percentages. aIndicates the differences between non-statin and statin groups. Abbreviation list: SBP, systolic blood pressure; DBP, diastolic blood pressure; TCHO, total cholesterol; TG, triglycerides; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; FPG, fasting plasma glucose; WMH, white matter hyperintensities; ICV, intracranial volume